Patient-friendly summary
If you read nothing else
Bottom line
Current fibromyalgia drugs offer limited benefit to a minority of patients and frequently cause side effects, so they should be part of an individualized, multimodal plan rather than used alone.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults with fibromyalgia, predominantly women in the cited trials, plus supporting animal-model research
Full research — for clinicians and curious readers
Study Summary
This narrative review summarizes the evidence on current and emerging drug treatments for fibromyalgia (FM), a chronic widespread-pain disorder commonly accompanied by fatigue, sleep disturbance, cognitive problems ("fibro fog"), and mood disorders, and widely regarded as a central sensitization syndrome. Only three medications — pregabalin, duloxetine, and milnacipran — have U.S. FDA approval, and the authors report that systematic reviews show these provide meaningful pain relief (around a 30% reduction) for only roughly 30%–40% of patients, while frequent adverse events drive low adherence and high discontinuation. Many other agents (cyclobenzaprine, gabapentinoids, NMDA antagonists, cannabinoids, sodium oxybate, low-dose naltrexone, iron, palmitoylethanolamide, and others) have been studied, but most remain investigational or limited by safety or weak evidence, and the authors note that several once-promising candidates (e.g., low-dose naltrexone, DHEA, alpha-1 antitrypsin) showed disappointing results in more rigorous recent trials.
The review concludes that pharmacotherapy alone is insufficient and should be combined with non-pharmacological strategies such as patient education, exercise, and psychological support within an individualized, multimodal plan.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Only three drugs are FDA-approved for fibromyalgia, and they help a minority of patients | The review states that only pregabalin, duloxetine, and milnacipran have U.S. FDA approval. Systematic reviews cited indicate these provide significant relief for approximately 30% of FM-related pain, with limited benefit for fatigue, sleep, and physical function. | High |
| Frequent adverse events lead to poor adherence and high discontinuation | The review reports pregabalin adverse-event rates around 85%-90%; adherence of only 47% (pregabalin), 43% (milnacipran), and 59% (duloxetine), with one-year discontinuation as high as 64.6%, 72.1%, and 51.5% respectively. | High |
| Duloxetine's benefit is modest, with a number-needed-to-treat of about 8 | A cited systematic review found the NNTB for 60 mg/day duloxetine to achieve at least 50% pain reduction is approximately 8, meaning only about one in eight treated patients reaches that threshold; a meta-analysis reported a small pain effect (SMD -0.26). | High |
| Amitriptyline and milnacipran may have advantages for specific symptoms | Cited reviews suggest amitriptyline showed the greatest improvement in sleep, fatigue, and quality of life among compared drugs, while milnacipran was more effective at relieving fatigue; amitriptyline trials are limited by small samples and low study quality. | Medium |
| No new FM drug has been approved in over a decade | The authors note it has been more than ten years since milnacipran was approved and, despite ongoing pharmaceutical efforts, no new drugs have gained approval; emerging agents such as sodium oxybate, ASP0819, ASP8062, NYX-2925, and TNX-102 SL (sublingual cyclobenzaprine) remain investigational. | Medium |
| Several once-promising drugs underperformed in rigorous recent trials | The review reports that recent larger, more rigorous trials suggest low-dose naltrexone may be ineffective for FM pain, and that DHEA and alpha-1 antitrypsin showed no significant symptom improvement versus placebo. | Medium |
| Drug therapy should be integrated with non-pharmacological care | The authors emphasize that guidelines recommend prioritizing non-pharmacological therapies (education, exercise, psychological support) and that medication alone is insufficient, yet over 90% of FM patients still seek medication-based treatment. | High |
Strengths
- Broad, up-to-date scope covering FDA-approved drugs, off-label agents, and investigational pipeline candidates through July 2024
- Prioritizes high-quality systematic reviews and Cochrane analyses when summarizing established drugs
- Reports concrete efficacy, adverse-event, adherence, and discontinuation data with effect sizes and confidence intervals from cited studies
- Honestly emphasizes the limited benefit of current pharmacotherapy and the need for multimodal, individualized care
- Addresses sex-related differences in presentation and diagnosis
Limitations
- Narrative review rather than a systematic review or meta-analysis, so study selection and synthesis are not formally standardized
- Cited evidence for many non-approved agents (e.g., venlafaxine, mirtazapine, gabapentin, cannabinoids, flupirtine) is limited, often from small or open-label trials
- Several promising treatments rely partly on animal-model data not yet confirmed in patients
- No new quantitative pooled analysis is performed by the authors themselves
- The article text available for this summary is truncated near the end (tramadol section onward), so some later content and the full conclusion are not captured here
Key Takeaways for Patients
What This Means for You
Fibromyalgia is a real, long-term pain condition often tied to how the nervous system processes pain (central sensitization), and it commonly comes with fatigue, poor sleep, brain fog, and mood changes.
Only three drugs are FDA-approved for fibromyalgia (pregabalin, duloxetine, milnacipran), and they meaningfully reduce pain for only a minority of people while frequently causing side effects.
Because side effects are common, many people stop these medications within a year, so finding the right drug and dose often takes patience and adjustment with your clinician.
Many other medications have been tried, but most are still experimental or have weak or mixed evidence, and some once-hopeful options did not work better than placebo in better-designed studies.
Medication alone is usually not enough; the review stresses combining drugs with exercise, education, and psychological support in a personalized plan.
If you have fibromyalgia, it may be worth being checked for iron deficiency, since the review notes possible benefit from treating low iron in those affected.
Read the Full Paper
Access the complete peer-reviewed study from Frontiers in Pharmacology